[Ketogenic diet: efficacy and tolerability in childhood intractable epilepsy]
Related Experiment Video
Updated: Oct 30, 2026

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
Published on: September 20, 2024
R Caraballo1, J Trípoli, L Escobal
1Servicio de Neurología, Hospital de Pediatría Juan P. Garraham, Buenos Aires, Argentina.
Insights
The ketogenic diet (KD) is effective for treating intractable epilepsies (IE) in children, with 50% of compliant patients showing significant seizure reduction and improved quality of life. This diet is generally well-tolerated by pediatric patients.
Area of Science:
- Neurology
- Pediatrics
- Clinical Nutrition
Context:
- Intractable epilepsies (IE) in children pose significant treatment challenges.
- Antiepileptic drugs (AEDs) are often insufficient for managing severe pediatric epilepsy.
- The ketogenic diet (KD) is an established alternative therapy for drug-resistant epilepsy.
Purpose:
- To evaluate the efficacy and tolerability of the classic ketogenic diet (KD) in children with intractable epilepsies (IE).
- To assess seizure frequency reduction and quality of life improvements in pediatric patients undergoing KD therapy.
- To determine the feasibility and acceptance of KD by children and their families.
Summary:
- Eighteen pediatric patients (ages 2-11) with intractable epilepsies were enrolled in a prospective study.
- Nine patients (64%) achieved sustained ketosis and adherence to the KD for at least two months.
- Of the compliant patients, 7 (50%) experienced a 50-75% reduction in seizures, and 4 (29%) had a 75-100% reduction.
Impact:
- The ketogenic diet (KD) demonstrates significant potential in reducing seizure frequency in children with intractable epilepsies (IE).
- KD therapy was well-tolerated by most pediatric patients and their families, improving quality of life.
- Further research with larger cohorts and longer follow-up is needed to fully understand KD's long-term effects and syndrome-specific efficacy.
Introduction:
Prospective study to evaluate efficacy of ketogenic diet (KD) in the treatment of children with intractable epilepsies (IE). Tolerability of the KD was also considered.
Material And Methods:
Criteria for inclusion were: 1. Epilepsy refractary to treatments with antiepileptic drugs (AED) in monotherapy and combining two or three AED. 2. Acknowledgment of blood levels of these drugs in therapeutic range. 3. Absence of liver or kidney disease, metabolic abnormalities, inborn errors of metabolism or other progressive encephalopathies. 4. Family supposedly in economic and psychologic conditions to accept the difficulties of strictly maintaining KD. We used a classic KD following the criteria suggested by the John Hopkins Pediatrics Epilepsy Center. Baseline neurological and physical examination, EEG, blood chemistry including lipid profile were obtained prior to initiative and during the KD. KD efficacy was measured as percent reduction of baseline seizures frequency, considering positive results as reductions of 50% or over. Acceptance of the diet and quality of life were specially considered. Eighteen patients with ages from 2 to 11 years were admitted. Ten of them were males. Diagnosis followed the last Classification of Epileptic Syndromes of the ILAE, and distribution was: Symptomatic partial epilepsies, 8 cases (one had West syndrome at age 5 months); cryptogenic partial epilepsies, 1 case; Lennox-Gastaut syndrome, 2 cases; severe myoclonic epilepsy of infancy, 6 cases and epilepsy with myoclonic astatic seizures 1 case.
Results:
Four patients were not able to achieve persistent ketosis either due to patient's rejection of KD or to parents non compliance. KD was kept for at least two months before considering failures. Five patients did not show significant improvement and KD was stopped. At present nine patients have been on KD from 6 to 24 months (average 16 months). Four of them showed a 75-100% reduction in seizures frequency and in three the reduction was of 50-75%.
Conclusions:
KD was fairly well tolerated by 14 of 18 children and their families. Fifty percent of the 14 patients complying KD showed significant improvement in seizure frequency and in quality of life. Due to the small number of patients and short follow-up, we can not speculate about results in relation to each epileptic syndrome, neither the risk of late complications.
More Related Videos
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
09:29Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
Published on: August 17, 2021
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Glutamate Antagonists
Pharmacokinetics in Pediatric Patients: Drug Metabolism